Drugs / PTX-35
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05116969 | Nov 2021 → Nov 2022 | — | Heat Biologics | Withdrawn | No outcome recorded |
| Phase 1 | NCT04430348 | Jun 2020 → Nov 2022 | neoplasm | Pelican Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04430348 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody PTX-35” NCT04430348 ↗ |
| Route | Intravenous | “intravenous administration of PTX-35” NCT04430348 ↗ |